<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397954</url>
  </required_header>
  <id_info>
    <org_study_id>OPH2002</org_study_id>
    <nct_id>NCT02397954</nct_id>
  </id_info>
  <brief_title>A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)</brief_title>
  <official_title>A Phase 2a Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthotech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthotech Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and tolerability of Zimura®
      intravitreous injection in combination with anti-VEGF therapy in subjects with Idiopathic
      Polypoidal Choroidal Vasculopathy (IPCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment experienced (Prior treatment with anti-VEGF monotherapy of ≥8 injections in the
      previous twelve (12) months) subjects with IPCV will receive 3 monthly (Q4W) injections of
      Zimura® in combination with anti-VEGF therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity Loss</measure>
    <time_frame>3 Months</time_frame>
    <description>Proportion of subjects with &gt;15 letter loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ophthalmic Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Occurrence of Ophthalmic Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Occurrence of Systemic Adverse Events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Idiopathic Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Zimura + Anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimura</intervention_name>
    <description>Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.</description>
    <arm_group_label>Zimura + Anti-VEGF</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Eylea</other_name>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either gender aged ≥ 50 years

          -  Diagnosis of IPCV

          -  Treatment-experienced defined as prior treatment with anti-VEGF mono therapy of ≥ 8
             injections in the previous twelve (12) months

        Exclusion Criteria:

          -  Any intraocular surgery or thermal laser within three (3) months of trial entry

          -  Any prior thermal laser in the macular region, regardless of indication

          -  Any ocular or periocular infection in the twelve (12) weeks prior to entry

          -  History of any of the following conditions or procedures in the study eye:
             Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g.
             trabeculectomy), glaucoma drainage device, corneal transplant

          -  Previous therapeutic radiation in the region of the study eye

          -  A diagnosis of diabetic retinopathy (presence of microaneurysms or any vasculopathy
             and/or leakage from retinal vasculature in a subject with diabetes mellitus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Pheonix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <disposition_first_submitted>April 4, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 4, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 5, 2017</disposition_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>idiopathic polypoidal choroidal vasculopathy</keyword>
  <keyword>IPCV</keyword>
  <keyword>Zimura®</keyword>
  <keyword>Avastin®</keyword>
  <keyword>Eylea®</keyword>
  <keyword>Lucentis®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

